Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties

  • Combination of Kiadis’ CD38 knock out K-NK cells with Sanofi’s anti-CD38 antibody Sarclisa® enables optimal tumor cell killing, and offers a potential first-in-class treatment for patients with multiple myeloma
  • Kiadis receives €17.5 million up front payment; potential for up to €857.5 million in preclinical, clinical, regulatory and commercial milestone payments, and up to double-digit royalties
  • Kiadis to hold conference call with investors and analysts at 16:00 CET today

Amsterdam, The Netherlands, July 8, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative natural killer cell therapies for patients with life-threatening diseases, today announces the exclusive license of Kiadis’ previously undisclosed K-NK004 program to Sanofi. The agreement covers Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutic for combination with anti-CD38 monoclonal antibodies, including Sarclisa®, Sanofi’s recently approved therapy for patients with multiple myeloma. Additionally, Sanofi has obtained exclusive rights to use Kiadis’ K-NK platform for two undisclosed pre-clinical programs.

As part of the agreement, Kiadis will receive a €17.5 million up front payment and will be entitled to receive up to €857.5 million upon Sanofi’s achievement of preclinical, clinical, regulatory and commercial milestones. Kiadis will also receive up to low double-digit royalties based on commercial sales of approved products resulting from this agreement.  

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections. Antibodies work synergistically with NK cells to kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity (ADCC). Treatment of multiple myeloma with anti-CD38 antibodies, such as Sarclisa®, deplete the patients’ own NK cells, as natural NK cells also express CD38. Kiadis’ CD38KO K-NK cells are NK cells that have been modified to prevent expression of CD38, and are thus resistant to this effect. Therefore, adjunctive infusion of CD38KO K-NK cells will reinvigorate the natural synergy between NK cells and antibodies to kill tumor cells, optimizing efficacy.

Arthur Lahr, chief executive officer of Kiadis, commented
, “We are proud to announce this collaboration with Sanofi, which marks the start of the previously undisclosed K-NK004 program and expands the application of our K-NK platform into multiple myeloma. The agreement with Sanofi –  with their world-class expertise and approved anti-CD38 monoclonal antibody, Sarclisa, in multiple myeloma and deep understanding of NK-cell biology – is a testament to the groundbreaking potential of our K-NK natural killer cell platform to treat life-threatening diseases.”

John Reed, Global Head of Research and Development at Sanofi, commented
, “The licensing of Kiadis’ CD38KO K-NK cells is particularly exciting for Sanofi since we will be studying this cell-based therapeutic with our recently FDA approved treatment for patients with difficult-to-treat multiple myeloma, in hopes of bringing even more options to these patients with this hematologic cancer. At Sanofi, we are committed to pioneering treatments that address unmet healthcare challenges. Innovative collaborations, such as this partnership with Kiadis, have the potential to expand the clinical benefits of our medicines by combining them with synergistic partnered therapeutics to deliver improved outcomes for patients.”

About the Sanofi-Kiadis License Agreement

Sanofi has received exclusive worldwide rights to research, develop and commercialize K-NK004 based on Kiadis’ CD38KO K-NK cells in combination with CD38-targeting molecules for the treatment of multiple myeloma and other CD38 positive blood cancers. Recently, Sanofi received U.S. Food and Drug Administration (FDA) approval for Sarclisa, a monoclonal antibody that targets CD38, for the treatment of multiple myeloma.  Additionally, Sanofi has obtained exclusive rights to use Kiadis’ K-NK platform for two other previously undisclosed pre-clinical programs. The license does not include rights to K-NK002 and K-NK003 or to any other current and future Kiadis programs.

Under the terms of this agreement, Sanofi will be responsible for and bear all costs related to the research and development, manufacturing, regulatory and commercial activities related to the licensed K-NK programs. Kiadis has retained exclusive rights to and will supply PM21 particles and select universal donors for Sanofi, paid for by Sanofi.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy,1 affecting more than 130,000 patients in the United States; approximately 32,000 Americans2 are diagnosed with multiple myeloma each year. Despite available treatments, multiple myeloma remains an incurable malignancy, and is associated with significant patient burden. As patients relapse, they can become refractory to therapies they have received. There is a need for new agents so that patients and physicians can have options as the disease progresses over time.

Conference Call Information

The call will begin promptly at 16:00 CET. To participate in the conference call, please call one of the following numbers ten minutes prior to commencement of the call:

  • Standard International: +44 (0) 2071 928338
  • Netherlands, Amsterdam: +31 (0) 207956614
  • UK, London: +44 (0) 8444819752
  • US, New York: 1-646-741-3167
  • US, toll free: 1-877-870-9135

Event Plus Passcode: 6366579#

A live webcast of the call can be accessed from the Events and Presentations section of the Company’s website,

Dutch Translation/Nederlandse vertaling

Amsterdam, 8 juli 2020 –

Kiadis Pharma N.V.

(“Kiadis” of de “Onderneming”) (Euronext Amsterdam en Brussel: KDS), een biofarmaceutische onderneming in de klinische fase gericht op ontwikkeling van innovatieve NaturalKiller Cell-therapieën voor patiënten met levensbedreigende aandoeningen, heeft een licentieovereenkomst gesloten met Sanofi voor Kiadis’ nog niet eerder bekendgemaakte preklinische K-NK004-programma. De overeenkomst geeft Sanofi het recht om Kiadis’ CD38 knock-out (CD38KO) K-NK-cel medicijn te combineren met Sanofi’s Sarclisa® anti-CD38 monoklonale antilichamen. Sarclisa® is recentelijk door de FDA goedgekeurd voor patiënten met multipel myeloom (ziekte van Kahler). Bovendien heeft Sanofi de exclusieve rechten verkregen voor het gebruik van Kiadis’ K-NK-platform voor twee niet nader genoemde preklinische programma’s.

Kiadis ontvangt een bedrag ineens van € 17,5 miljoen en heeft het recht op totale betalingen tot potentieel € 857,5 miljoen, zodra Sanofi vooraf vastgestelde mijlpalen heeft behaald. Kiadis zal daarnaast tot lage dubbelcijferige royalty’s ontvangen op de omzet van producten die door Sanofi worden ontwikkeld als onderdeel van de overeenkomst.

Natural killer (NK)-cellen vormen de eerste verdedigingslinie van het menselijk lichaam tegen kanker en infecties. Antilichamen werken in het menselijk lichaam samen met NK-cellen voor het doden van tumorcellen. Anti-CD38-antilichamen voor de behandeling van multipel myeloom (ziekte van Kahler), zoals Sarclisa®, doden echter niet alleen de tumorcellen die CD38 tot expressie brengen, maar ook de eigen NK-cellen van de patiënt, aangezien deze ook CD38 tot expressie brengen. Kiadis’ CD38KO K-NK-cellen brengen CD38 niet tot expressie en zijn daarmee resistent tegen dit effect. Een combinatietherapie met zowel anti-CD38 antilichamen als CD38KO K-NK-cellen herstelt daarmee de natuurlijke synergie tussen NK-cellen en antilichamen en optimaliseert de anti-tumor effectiviteit.

Arthur Lahr, CEO van Kiadis, zegt in reactie:

“Het is met trots dat we deze samenwerking met Sanofi bekendmaken. Deze alliantie markeert de start van ons nog niet eerder bekendgemaakte K-NK004-programma en breidt de toepassing van onze K-NK-medicijnen uit naar multipel myeloom. Sanofi heeft het door de FDA goedgekeurde anti-CD38-antilichaam
op de markt voor de behandeling van deze ziekte en bezit een diepgaande kennis van NK-celbiologie en synergie met antilichamen. De overeenkomst getuigt daarmee van het baanbrekende potentieel van ons K-NK natural killer cell-platform voor de behandeling van levensbedreigende aandoeningen.”

John Reed, MD, PhD, global head of research and development van Sanofi, zegt:

“De licentie van Kiadis ‘CD38KO K-NK-cellen is voor Sanofi bijzonder interessant. We zullen deze celtherapie gaan combineren met ons onlangs door de FDA goedgekeurde medicijn voor patiënten met moeilijk te behandelen multipel myeloom. We hopen zo patiënten met deze bloedkanker meer opties te kunnen bieden. Bij Sanofi zetten we ons in voor baanbrekende behandelingen om grote medische problemen aan te pakken. Innovatieve allianties zoals die met Kiadis kunnen de klinische voordelen van onze geneesmiddelen vergroten, door combinatie met synergetische geneesmiddelen, om resultaten voor patiënten te verbeteren.”

De overeenkomst met Sanofi

Sanofi heeft de exclusieve wereldwijde rechten gekregen om Kiadis’ CD38KO K-NK-cellen te ontwikkelen en op de markt te brengen in combinatie met op CD38-gerichte moleculen voor de behandeling van multipel myeloom en andere CD38-positieve bloedkankers. Onlangs ontving Sanofi goedkeuring van de Amerikaanse Food and Drug Administration (FDA) voor Sarclisa®, een monoklonaal antilichaam dat zich richt op CD38, voor de behandeling van multipel myeloom (Ziekte van Kahler). Daarnaast heeft Sanofi de exclusieve rechten verkregen om het K-NK-platform van Kiadis te gebruiken voor twee andere niet nader genoemde preklinische programma’s. De licentie omvat geen rechten op K-NK002 en K-NK003 of op andere huidige en toekomstige Kiadis-programma’s.

Conform de voorwaarden van deze overeenkomst is Sanofi verantwoordelijk voor en draagt het alle kosten in verband met onderzoek, ontwikkeling, productie, regulatoire activiteiten en verkoop van de gelicentieerde K-NK-programma’s. Kiadis heeft de exclusieve rechten behouden om PM21-deeltjes aan Sanofi te leveren en universele donoren voor Sanofi te selecteren, bekostigd door Sanofi.

Dit bericht is een vertaling van het originele Engelstalige persbericht. In geval van verschillen ten gevolge van vertaling of verschillen in interpretatie, geldt het originele Engelstalige persbericht als leidend.

Kiadis Contacts:


Maryann Cimino, Sr. Manager, Corporate Affairs
Tel: +1 (617) 710-7305


Optimum Strategic Communications:
Mary Clark, Supriya Mathur
Tel: +44 203 950 9144

LifeSpring Life Sciences Communication (NL)
Leon Melens
Tel:  +31 (0)6 538 16 427

About Kiadis’ K-NK-Cell Therapies

Kiadis’ K-NK platform is designed to deliver potent NK cells to help patients. Kiadis’ programs consist of off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. 

The Company’s PM21 particle technology enables improved ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions. Kiadis’ proprietary off-the-shelf NK-cell platform is based on NK cells from unique universal donors and can make NK-cell therapy product rapidly and economically available for a broad patient population across a wide range of indications.

Kiadis is developing K-NK002 as an adjunctive immunotherapeutic on top of HSCT, and K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. In addition, Kiadis has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors. 

About Kiadis

Founded in 1997, Kiadis is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at

Forward Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Sarclisa® is a registered trademark of Sanofi. For important safety information for Sarclisa, please click here

1 Kazandjian. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676-681. doi:10.1053/j/seminoncol.2016.11.004
2  National Cancer Institute. Myeloma Cancer Stat Facts. Available at: Accessed on July 7, 2020.

WISeKey IoT Cybersecurity Allows Electric Vehicles to Securely Communicate with Charging Stations and Network of Vehicles

WISeKey IoT Cybersecurity Allows Electric Vehicles
to Securely Communicate with Charging Stations and Network of Vehicles

GENEVA – July 8, 2020 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN / Nasdaq: WKEY), a leading Swiss cybersecurity and IoT company today announced that is combining software and microchips to allow Electric Vehicles (EVs) to securely communicate with charging stations, the network of connected vehicles, and even the electrical grid.

The company has shown strong growth and made tremendous progress on the EV and Connected Vehicle industry with the signing of strategic partnerships with leading European automobile manufacturers.   WISeKey’s initial application was based on the integration of the WISeKey IoT and Public Key Infrastructure (PKI) in the manufacturers connected car solutions which allowed them to authenticate legitimate car components and enabled owners to securely interact with the car’s smart features. This technology has been upgraded to allow EVs and charging stations to securely communicate using network segmentation technologies to reduce the associated risk.

EV charging stations are an existing risk as attackers can compromise the security of the electronic charging stations to cause damage.  This is often done through the Near-Field Communication (NFC) card that is used to handle billing when drivers charge their EVs as third-party providers of these ID cards, often do not secure their customer data.

WISeKey’s solutions reduce EV’s potential security threats by providing:

  • IoT “secure element” chips, essentially a small smartcard, that can be embedded into different components of the car to enhance the security of their electronic functions.
  • Highly-scalable and reliable PKI to create the electronic credentials that assert the identity of the device or authorized users and enables encryption to protect data or software integrity. These PKI solutions are highly adaptable to both the “lightweight” technology needs of IoT and the changing attributes of IoT devices over time after the vehicle has left the car factory.

In short, the WISeKey IoT solutions benefit both:  the manufacturer by providing cost-effective solution to secure car components and their related online services, and also drivers in securing the massive amount of data produced by smart cars in daily use – which includes significant detail on the driver’s personal behavior and movements, similar to that produced by a smartphone.

Additionally, many of the charging stations today use an outdated Open Charge Point Protocol based on HTTP, which does not encrypt data or communications. This could lead to relay or man-in-the-middle attacks where attackers leverage a seemingly legitimate signal such as Wi-Fi. This vulnerability could also allow attackers to rewire charging requests altogether, and gain root access to the station. USB ports on charging stations could also be used for malicious intent that could directly affect driver privacy. Through a simple flash drive, logs and data can be copied to the drive, giving attackers not only the data on the OCPP server itself, but also confidential information on users of the charging point, allowing attackers to copy their ID numbers or even track their location.

WISeKey Machine to Machine digital certificates and microchips like NanoSeal allow connected cars to connect securely at the Electric Charging Stations, completing the transaction without using credit cards or any other traditional payment.  Connected car owners can charge their cars and pay by transferring the credit via NFC technology directly from their mobiles or from their car wallet to the Electric Charging Station. WISeKey’s Digital certificate stored on a WISeKey Microchip acts as a secure hardware module which securely sends payment transactions between the electric car and the electric charger without any intermediaries or paying any transactional fees.

WISeKey IoT for EVs also includes an unforgeable Digital Identification for the EV and eCharger, securing both.   Virtually all new cars on the market today include electronic technologies that could pose vulnerabilities to hacking or privacy intrusions if data security is not addressed.   For example, smart cars without cybersecurity protection technology could allow hackers to gain remote access by exploiting vulnerabilities in their ecosystem of connected components and online services.  As the number of cars connected to the Internet is growing quickly (to over a quarter of a billion by year 2020, as estimated by Gartner), smart car manufactures are working to identify and reduce potential hacking vulnerabilities in their vehicles.  BI Intelligence expects 94 million connected cars to be sold in 2021, and for 82% of all cars sold during that year to be connected. This represents a compound annual growth rate of 35%, from 21 million connected cars in 2016. In recent years, the security protections of smart cars have expanded using proven IoT technologies. There is increased use of “secure element” chips provided by WISeKey Semiconductor to authenticate individual car components within the vehicle itself and to the online services it interacts with, and to ensure that only legitimate software is installed in the car.

In recent years, security protections of smart cars have expanded using proven IoT technologies.  There is an increased use of “secure element” chips provided by WISeKey Semiconductor to authenticate individual car components within the vehicle itself and to the online services it interacts with, and to ensure that only legitimate software is installed in the car. 

“As cars continue to evolve, essentially becoming motorized computers, they are vulnerable to the very same threats and attacks as home computers, laptops and smartphones.  Unless appropriate cybersecurity measures are implemented, hackers can remotely access the vehicle’s computer system, manipulate the brakes, engine, and transmission. Our technology is designed to help verify legitimate car systems, protect the data they create and avoid malicious hacking,” said Carlos Moreira, CEO of WISeKey.

About WISeKey

WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large scale digital identity ecosystems for people and objects using Blockchain, AI and IoT respecting the Human as the Fulcrum of the Internet. WISeKey microprocessors secure the pervasive computing shaping today’s Internet of Everything. WISeKey IoT has an install base of over 1.5 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens etc.).  WISeKey is uniquely positioned to be at the edge of IoT as our semiconductors produce a huge amount of Big Data that, when analyzed with Artificial Intelligence (AI), can help industrial applications to predict the failure of their equipment before it happens.

Our technology is Trusted by the OISTE/WISeKey’s Swiss based cryptographic Root of Trust (“RoT”) provides secure authentication and identification, in both physical and virtual environments, for the Internet of Things, Blockchain and Artificial Intelligence. The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people. For more information, visit

Press and investor contacts:

WISeKey International Holding Ltd
Company Contact:  Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
WISeKey Investor Relations (US)
Contact:  Lena Cati
The Equity Group Inc.
Tel: +1 212 836-9611


This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.

Northern Trust Appointed by Azimut (DIFC) Limited to Deliver Asset Servicing and Portfolio Reporting Services

Northern Trust Appointed by Azimut (DIFC) Limited to Deliver Asset Servicing and Portfolio Reporting Services

ABU DHABI, United Arab Emirates & DUBAI, United Arab Emirates–(BUSINESS WIRE)–
Northern Trust (Nasdaq: NTRS) announced today that it has been appointed by Azimut (DIFC) Limited to provide asset servicing and portfolio reporting for its Dubai International Financial Centre (DIFC) funds in the Middle East.

Azimut (DIFC) Limited’s Dubai-managed funds provide its investors with access to a range of investment strategies, private wealth solutions and mutual funds, both proprietary and third-party. As custodian for its DIFC fund range, Northern Trust will deliver portfolio reporting and local servicing in its client’s time zone directly from the United Arab Emirates.

Azimut (DIFC) Limited is part of the Azimut Group – one of Italy’s leading independent asset managers with €54.5 billion of assets under management (as of 31 May 2020). Headquartered in Milan, the group was founded in 1989 and is listed on the Italian stock exchange.

Michael Slater, head of Middle East and Africa at Northern Trust comments: “Azimut is a prominent European asset manager requiring a Middle East asset servicing solution. The combination of Northern Trust’s technology, local presence and ability to provide global custody in over a hundred countries supports Azimut’s strategic growth objectives by delivering servicing and solutions in its working week and time zone. Our business supporting Middle East funds continues to grow – underpinned by our global scale and expertise in supporting the full spectrum of investment strategies.”

Giorgio Medda, global head of Asset Management and Azimut Group Co-CEO, said: “As we continue to grow our investment solutions offering for our clients in the Middle East, we are committed to providing them with efficient and best-of-class services. Northern Trust’s multi-asset class expertise, technology platform and sound financial standing offer us a solid and secure base for our ambitious expansion plans.”

Northern Trust began servicing clients in the Middle East in 1987. Today, from its offices in Abu Dhabi and Riyadh, it provides a comprehensive range of solutions to a portfolio of clients that include many of the largest sovereign wealth funds, central banks, inter-governmental/governmental organizations, asset managers and family offices in the region.

About Northern Trust

Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 22 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of March 31, 2020, Northern Trust had assets under custody/administration of US $10.9 trillion, and assets under management of US $1.1 trillion. For more than 130 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit or follow us on Twitter @NorthernTrust.

Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at

About Azimut (DIFC) Limited

Azimut is Italy’s leading independent asset manager (active since 1989). The parent company Azimut Holding was listed on the Italian stock exchange on 7 July 2004 (AZM.MI) and, among others, is a member of the main Italian index FTSE MIB. The shareholder structure includes over 1,900 managers, employees and financial advisors, bound by a shareholders’ agreement that controls c. 21% of the company. The remaining is free float. The Group comprises various companies active in the sale, management and distribution of financial and insurance products, with Registered Offices mainly in Italy, Luxembourg, Ireland, China (Hong Kong and Shanghai), Monaco, Switzerland, Taiwan, Brazil, Egypt, Singapore, Mexico, Australia, Chile, USA, UAE and Turkey. In Italy, Azimut Capital Management SGR sells and manages Italian mutual funds, Italian alternative investment funds, as well as being active in the discretionary management of individual investment portfolios. Furthermore, Azimut Capital Management SGR, following the demerger by incorporation of Azimut Consulenza SIM, distributes Group and third party products in Italy via a network of financial advisors while Azimut Libera Impresa focuses on the Alternatives business. Overseas main operations are Azimut Investments SA (formerly AZ Fund Management founded in Luxembourg in 1999), which manages the multi strategy funds AZ Fund 1 and AZ Multi Asset and the Irish AZ Life DAC, which offers life insurance products.

# # #

Media Contacts, Northern Trust

Europe, Middle East, Africa & Asia-Pacific:

Camilla Greene

+44 (0) 20 7982 2176

Marcel Klebba

+44 (0) 20 7982 1994

US & Canada:

John O’Connell

+1 312 444 2388


Azimut Group

Investor Relations

Vittorio Pracca

+39 02 8898 5853

Galeazzo Cornetto Bourlot

+39 02 8898 5066

Media Relations

Maria Laura Sisti (Esclapon)

+39 347 42 82 170

Viviana Merotto

+39 02 8898 5026

KEYWORDS: Middle East United Arab Emirates

INDUSTRY KEYWORDS: Finance Consulting Banking Professional Services Other Professional Services



Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets, 500mg and 1000mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity

PR Newswire

BALTIMORE, July 8, 2020 /PRNewswire/ —  Lupin Pharmaceuticals Inc. is voluntarily recalling all batches of Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg to the consumer level. As part of the ongoing assessment and continuation of the dialog with the FDA, additional analysis revealed that certain tested batches were above the Acceptable Daily Intake Limit for the impurity N-Nitrosodimethylamine (NDMA). Out of an abundance of caution, the company is recalling all batches of Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg in the US. To date, Lupin Pharmaceuticals Inc. has not received any reports of adverse events related to this recall.

Risk Statement: NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products and vegetables.

Metformin Hydrochloride Extended-Release Tablets USP is a prescription oral medication indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus. Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg is packaged in 60, 90 and 100 count bottles and was distributed nationwide in the US to wholesalers, distributors, drug chain, mail order pharmacies and supermarkets. The recalled NDC’s are included in the table below:




Distribution Dates





11/21/2018 – 05/27/2020





11/05/2018 – 05/22/2020



Lupin Pharmaceuticals Inc. is notifying its wholesalers, distributors, drug chain, mail order pharmacies and supermarkets by phone and through recall notification and is arranging for the return of all the recalled product NDC’s. 

Patients taking Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 1000mg, are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment. According to the U.S. Food & Drug Administration, it could be dangerous for patients with this serious condition to stop taking their metformin without first talking to their health care professionals. Please visit the agency’s website for more information at

Wholesalers, distributors, and retailers that have Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg that are being recalled should discontinue distribution of the recalled product NDC’s immediately and return it to Inmar Rx Solutions, Inc., 635 Vine St, Winston Salem, NC 27101. Tel: (855) 532-1856.

Consumers, wholesalers, distributors, and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (855) 532-1856 Monday – Friday 09:00 am to 05:00 pm EST. For reimbursement, please have the recalled NDC’s returned to Inmar Rx Solutions, Inc.; the NDC number can be found on the top of the bottle label.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

About Lupin Pharmaceuticals

Lupin Pharmaceuticals, Inc. is the U.S. based wholly owned subsidiary of Lupin Limited and is the 3rd largest pharmaceutical company in the U.S. based on total prescriptions. Together, all Lupin-owned entities combine to make up the 8th largest generic pharmaceutical company in the world by revenue size. Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality medications across many treatment areas. Lupin Pharmaceuticals Inc.’s branded pharmaceuticals division, is the provider of products designed to help prevent and manage women’s health conditions with serious health consequences.

© 2020 Lupin Pharmaceuticals, Inc. All rights reserved.

Company Contact:

Arvind Bothra


Cision View original content to download multimedia:–n-nitrosodimethylamine-ndma-impurity-301089754.html

SOURCE Lupin Pharmaceuticals, Inc.

Tencent Music Entertainment Exclusively Presents “Global Goal: Unite for Our Future” Special in China

PR Newswire

SHENZHEN, China, July 8, 2020 /PRNewswire/ — Today, Tencent Music Entertainment (TME) (NYSE:TME) announced it will be the exclusive strategic partner in China of Global Goal: Unite for Our Future—The Concert, a globally televised and digitally streamed special that will highlight the disproportionate impact COVID-19 has on marginalized communities and support equal access to COVID-19 care. The program will stream on QQ Music, Kugou Music, Kuwo Music and WeSing at 12 p.m., July 8 via TME live.

The Concert will feature performances from Chloe x Halle, Christine and the Queens, Coldplay, J Balvin, Jennifer Hudson, Justin Bieber & Quavo, J’Nai Bridges with Gustavo Dudamel, Los Angeles Philharmonic & YOLA (Youth Orchestra Los Angeles), Miley Cyrus, Shakira, Usher and Yemi Alade.

The Global Goal: Unite for our Future campaign was launched last month under the patronage of European Commission President Ursula von der Leyen. The campaign focuses on addressing the pandemic’s impact on the most vulnerable, and seeks to build back communities and economies with freedom and justice for all. Calling on individuals to take action, and asking governments, corporate leaders and philanthropists to make their commitments toward the fair distribution of COVID-19 tests, treatments, and vaccines, Global Goal: Unite for our Future aims to strengthen healthcare systems so no one is left behind in this pandemic.

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME) is the leading online music entertainment platform in China, operating the country’s highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME’s mission is to use technology to elevate the role of music in people’s lives by enabling them to create, enjoy, share and interact with music. TME’s platform comprises online music, online karaoke and music-centric live streaming services, enabling music fans to discover, listen, sing, watch, perform and socialize around music.

For more information, please visit

Media Contact: 

Edmond Lococo, ICR Inc.
Phone: +86-138 1079 1408

Cision View original content:

SOURCE Tencent Music Entertainment Group

Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

SAN FRANCISCO, July 08, 2020 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases,  announced it has initiated in Brazil a randomized, placebo-controlled Phase 2 proof-of-concept trial of ANG-3777 plus standard of care in patients with acute lung injury associated with COVID-19 pneumonia.

“Given the potential of ANG-3777 to broadly address acute organ injury, we believe it is important to investigate its ability to mitigate or prevent acute lung injury in patients who have been hospitalized with COVID-19 pneumonia,” commented John Neylan, M.D., Angion’s Senior Vice President and Chief Medical Officer. “We are commencing this study in Brazil, which continues to be tremendously impacted by COVID-19 and where we are conducting another clinical trial of ANG-3777 in patients with acute kidney injury involving cardiopulmonary bypass surgery.” 

The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia. The primary endpoint of the trial is the proportion of patients alive, without the need for mechanical ventilation and free of the need for renal replacement therapy (on an ongoing basis) at day 28. Angion expects to enroll approximately 100 patients in the trial. Patients will be randomized at a ratio of one-to-one to receive four intravenous doses of 2.0 mg/kg of ANG-3777 plus standard of care versus placebo plus standard of care. This ANG-3777 dosing regimen was previously approved for investigational use in Brazil, allowing for a quicker initiation of this trial for a population in need. If the Phase 2 trial is successful in patients with acute lung injury associated with COVID-19 pneumonia, we intend to submit an investigational new drug application (IND) in the United States

“While anti-viral therapies are most welcome in our effort to help patients with COVID-19, front-line physicians need additional tools to address the acute lung injury often seen in these patients,” commented Gregory P. Downey, MD, a pulmonologist at National Jewish Health in Denver, Colorado and a member of Angion’s Scientific Advisory Board. “I’m hopeful data from this trial will show ANG-3777 can be another tool to help address the needs of patients impacted by this pandemic.”

The clinical rationale for this Phase 2 clinical trial of ANG-3777 in patients with acute lung injury associated with COVID-19 pneumonia is rooted in the compelling activity ANG-3777 has shown in several preclinical in vivo models of acute lung injury such as radiation-induced lung injury, chlorine (Cl2)-induced acute lung injury, bleomycin-induced pulmonary edema, TGFβ1-induced mortality and lung fibrosis, lipopolysaccharide (LPS)-induced shock, and lung ischemia-reperfusion injury.

Following the completion of a Phase 2 clinical trial of ANG-3777, Angion is currently conducting a Phase 3 registration trial of ANG-3777 to improve kidney function and reduce the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients showing evidence of early kidney dysfunction and in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass.

Additional details on the Phase 2 clinical trial can be found at (NCT #04459676)

About ANG-3777

ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the c-Met cascade of pathways involved in tissue repair and organ repair. ANG-3777 has a substantially longer half-life than HGF and we believe ANG-3777 has the potential to be a first-in-class therapeutic addressing acute organ injury. The ongoing clinical trials of ANG-3777 include a placebo-controlled Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 proof-of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery, and a Phase 2 proof-of-concept trial in patients with acute lung injury associated with COVID-19 pneumonia.

About Angion Biomedica Corp.

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion’s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for fibrotic diseases using a precision-medicine approach. For further information, please visit

Investor Contact

Daniel Ferry
LifeSci Advisors 

Media Contact

Cherilyn Cecchini, M.D.
LifeSci Communications 

60% Are Willing to Risk Their Health To Vote In Person In November

PR Newswire

MOUNTAIN VIEW, Calif., July 8, 2020 /PRNewswire/ — Sacrificing one’s health to vote in the November election: 60% are willing to risk their health to vote in person, according to the latest consumer pulse survey. 63% of Americans don’t think healthcare should be a political issue. Yet when asked what the most important issue is to them in the 2020 election, 50% said economy and 50% said healthcare.

Beyond the 2020 election, the survey explored COVID-19’s impact on healthcare, health insurance, medical costs, technology, and the economic landscape.

Medical costs were a top concern for the majority of respondents:

  • 92% think prescription drug prices in the U.S. are too high
  • 93% think medical costs in the U.S. are too high
  • 56% have avoided medical treatment because of cost
  • 64% think they pay too much for health insurance
  • 93% think prices for medical procedures should be as transparent as prices of food in the supermarket

COVID-19 also remained a prominent worry for many respondents. Two-thirds reported feeling less confident in the quality of healthcare in the United States in light of COVID-19. 1 in 4 has or knows someone who has tested positive for COVID-19. Yet, testing is an issue, with one-third of respondents reporting having a hard time or knowing someone who had a hard time getting tested for COVID-19. Lastly, 63% reported being worried over the cost of COVID-19 treatment.

The recent spike in COVID-19 cases has 74% thinking the U.S. needs another “pause” to contain the spread. Another 88% said they would comply if the country has to shut down again to contain COVID-19.

With 89% saying they are taking every precaution possible to prevent getting COVID-19, 62% say they have witnessed guidelines not being followed while out in public places.  For cities or towns that have partially opened:

  • 40% have been to a restaurant or bar
  • 37% have been to a beauty/hair salon or barber shop
  • 60% have been to a retail store or mall
  • 14% have been to a gym

When asked about masks, 85% think they prevent the spread of COVID-19 with 77% saying everyone should be required to wear one. In fact, 73% think there should be a fine for not wearing a mask, and 41% think the fine should be more than $100.

Traveling anywhere is out of the question for most. 53% reported not being comfortable returning to the office just yet, and 67% say they wouldn’t travel for work or to see family members or friends.

Working from home has 47% finding it impossible to find a way to completely unplug from the office. For the majority, that’s a trade-off they are willing to make: 81% said they want to work from home full-time after COVID-19 passes – and 43% would even take a pay cut to do so.

Healthcare technology continues to be on the rise now more than ever:

  • Before the COVID-19 pandemic, 20% had used telemedicine.
  • During the pandemic, 43% have used telemedicine.
  • After the pandemic, 60% say they will continue to use telemedicine.
  • 56% say their doctors are offering virtual visits and 3 in 10 say their insurance companies have been in touch about telemedicine.

Telemedicine isn’t just for humans, though. 49% said they would use telemedicine for their fur babies. The survey also asked pet owners how COVID-19 is impacting their pets; 37% will stop allowing people to pet their dog over COVID-19 fears, while 17% are afraid their pet is going to get COVID-19.

COVID-19 is leaving many thinking about their insurance options, too. 56% say they have a life insurance policy, but COVID-19 has caused 31% of respondents to think about buying one. 20% has lost or knows someone that has lost their health insurance during COVID-19. 54% say they don’t know what their health insurance options are should they lose their health insurance – a decrease from the 68% that didn’t know their options in May. While many may be thinking about getting a new job, 49% are reluctant to switch jobs right now because they want to keep their health benefits.

View the full survey results here:

The above results were gathered through an online poll of more than 1,100 Americans between the ages of 18-64. The poll was conducted from July 3, 2020 to July 6, 2020, gleaning representative samples from each state based on population.

ABOUT HEALTHINSURANCE.COM: combines the nation’s leading health insurance carriers and advanced technology to offer a suite of private insurance solutions and Medicare plan options. In just a few clicks, our website provides consumers the ability to access powerful online comparison tools and educational resources that enable efficient self-guided navigation of available health insurance and Medicare options. For more information, visit

FORWARD-LOOKING STATEMENTS: LLC is part of the Benefytt Technologies family companies (NASDAQ: BFYT). This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical fact, and may include statements relating to goals, plans and projections regarding new markets, products, services, growth strategies, anticipated trends in our business and anticipated changes and developments in the United States health insurance system and laws. Forward-looking statements are based on our current assumptions, expectations and beliefs are generally identifiable by use of words “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” or similar expressions and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, among other things, our ability to maintain relationships and develop new relationships with health insurance carriers and distributors, our ability to retain our members, the demand for our products, the amount of commissions paid to us or changes in health insurance plan pricing practices, our ability to integrate our acquisitions, competition, changes and developments in the United States health insurance system and laws, and our ability to adapt to them, the ability to maintain and enhance our name recognition, difficulties arising from acquisitions or other strategic transactions, and our ability to build the necessary infrastructure and processes to maintain effective controls over financial reporting. These and other risk factors that could cause actual results to differ materially from those expressed or implied in our forward-looking statements are discussed in HIIQ’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) as well as other documents that may be filed by HIIQ from time to time with the Securities and Exchange Commission, which are available at Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. You should not rely on any forward-looking statement as representing our views in the future. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Cision View original content to download multimedia:


Televisa Reports Second Quarter 2020 Results

PR Newswire

MEXICO CITY, July 7, 2020 /PRNewswire/ —


  • Revenues reached Ps.22.4 billion
  • Operating Segment Income (“OSI”) margin reached 35.8%
  • Standard & Poor´s and Fitch Ratings ratified Televisa’s BBB+ ratings
  • Strong demand for connectivity services due to social distancing policies
  • Other Businesses segment significantly impacted by the shut down of the economy


  • Record growth of 494 thousand Revenue Generating Units (“RGUs”)
  • New record in broadband RGUs net adds of 252 thousand for a single quarter
  • Strong top line growth of 10.7% and OSI growth of 4.1%
  • Launched izzi Móvil, a MVNO (Mobile Virtual Network Operator)


  • 72 thousand new broadband RGUs reaching over 500 thousand
  • 5th consecutive quarter of growth in video RGUs after adding 20 thousand
  • Revenues grew 3.1%, the fastest pace of growth in 13 quarters
  • OSI resumed growth, reaching Ps.2.3 billion


  • Audience growth y-o-y of 18%[1] in our flagship network
  • Advertising revenue drop of 33.1% due to shut down of economy
  • Revenues were down 16.3% and OSI margin reached 30.9%
  • Savings from cost and expenses reduction program of Ps.462 million

Earnings Call Date and Time: Wednesday, July 8, 2020, at 10:00 A.M. ET.

Conference ID # is 8059865
From the U.S.: +1 (877) 850 2115                                                      From Mexico: 800 926 9157
International callers: +1 (478) 219 0648                                           Rebroadcast: +1 (404) 537-3406

The teleconference will be rebroadcast starting at 13:00 ET on July 8 through midnight on July 22.

1 Source: Nielsen. P4+, Monday to Sunday, 16:30 to 23:00

Consolidated Results

Grupo Televisa, S.A.B. (NYSE:TV; BMV: TLEVISA CPO; “Televisa” or “the Company”), today announced results for second-quarter 2020. The results have been prepared in accordance with International Financial Reporting Standards (“IFRS”).

The following table sets forth condensed consolidated statements of income for the quarters ended June 30, 2020 and 2019, in millions of Mexican pesos:









Net sales






Net income






Net income attributable to stockholders of the Company






Segment net sales






Operating segment income (1)






(1)  The operating segment income margin is calculated as a percentage of segment net sales.

Net sales decreased by 7.8% to Ps.22,407.2 million in second-quarter 2020 compared with Ps.24,307.6 million in second-quarter 2019. This decrease was mainly attributable to a decline in Advertising sales and in Other Businesses. Operating segment income decreased by 12.4% to Ps.8,636.3 million with a margin of 35.8%, due to the decline in operating segment income of Content and Other Businesses segments.

Net income attributable to stockholders of the Company increased to Ps.1,739.5 million in second-quarter 2020 compared to Ps.919.1 million in second-quarter 2019.

The net increase of Ps.820.4 million reflected:

i.  a Ps.2,179.6 million decrease in finance expense, net; and
ii.  a Ps.94.4 million decrease in net income attributable to non-controlling interests.

These favorable variances were partially offset by:

i.  a Ps.1,251.4 million decrease in operating income before depreciation and amortization and other expense, net;
ii.  a Ps.154.9 million increase in depreciation and amortization;
iii.  a Ps.10.5 million increase in other expense, net;
iv.  a Ps.26.2 million decrease in share of income of associates and joint ventures, net; and v.  a Ps.10.6 million increase in income taxes.

Second-quarter Results by Business Segment

The following table presents second-quarter consolidated results ended June 30, 2020 and 2019, for each of our business segments. Consolidated results for second-quarter 2020 and 2019 are presented in millions of Mexican pesos.

Net Sales

























Other Businesses






Segment Net Sales






Intersegment Operations1



Net Sales




Held-for-sale Operations 2






Net Sales





Operating Segment Income3



























Other Businesses






Operating Segment Income            






Corporate Expenses






Depreciation and Amortization






Other Expense, net






Intersegment Operations






Held-for-sale Operations 2






Operating Income






1 For segment reporting purposes, intersegment operations are included in each of the segment operations.

2 The assets and related liabilities of the Radio business are classified as held for sale in the Company’s consolidated statement of financial position as of June 30 , 2020 and December 31, 2019. Accordingly, the net sales and the operating segment income associated with the Radio business, which was part of the Company’s Other Businesses segment, are presented separately as held-for-sale operations for the quarters ended June 30, 2020 and 2019. The sale of the Radio business was concluded on July 2nd, 2020.

3 Operating segment income is defined as operating income before depreciation and amortization, corporate expenses, and other expense, net.


Total net additions for the quarter were approximately 494.1 thousand RGUs. Quarterly growth was mainly driven by record broadband net additions of 252.2 thousand and voice net additions of 214.5 thousand. Video net additions increased by 27.4 thousand. The following table sets forth the breakdown of RGUs per service type for our Cable segment as of June 30, 2020 and 2019.


2Q’20 Net Adds















Total RGUs




Second-quarter sales increased by 10.7% to Ps.11,308.8 million compared with Ps.10,215.7 million in second-quarter 2019 driven by solid net additions in broadband and voice.

Second-quarter operating segment income increased by 4.1% to Ps.4,656.5 million compared with Ps.4,473.7 million in second-quarter 2019. Margin decreased by 260 basis points to 41.2% due to a number of reasons, such as strong growth in our lower-margin packages that are bundled with OTT services, promotions around fixed line portability, and promotions to drive a higher adoption of automatic recurring payments.

The following tables set forth the breakdown of revenues and operating segment income, excluding consolidation adjustments, for our MSO and enterprise operations for second-quarter 2020 and 2019.

MSO Operations

Millions of Mexican pesos



Change %





Operating Segment Income




Margin (%)




Enterprise Operations (1)

Millions of Mexican pesos



Change %





Operating Segment Income




Margin (%)




(1)  These results do not include consolidation adjustments of Ps.409.1 million in revenues nor Ps.143.7 million in operating segment income for second quarter 2020, neither the consolidation adjustments of Ps.413.9 million in revenues nor Ps.108.0 million in operating segment income for second quarter 2019. Consolidation adjustments are considered in the consolidated results of the Cable segment.

Second-quarter sales and operating segment income in our MSO operations increased by 7.7% and 2.8%, respectively. Second-quarter sales and operating segment income in our Enterprise operations increased by 26.6% and 19.9%, respectively.

On June 20th we launched izzi Móvil, an MVNO (Mobile Virtual Network Operation) that will use the network of Altan (Red Compartida project).


During the quarter, Sky continued growing its broadband business after adding 72.0 thousand broadband RGUs reaching a total of 502.4 thousand broadband RGUs. In addition, Sky added 19.7 thousand video RGUs. This is the 5th consecutive quarter of video RGU net additions.

The following table sets forth the breakdown of RGUs per service type for Sky as of June 30, 2020 and 2019.


2Q’20 Net Adds















Total RGUs




 Second-quarter sales increased by 3.1% to Ps.5,514.7 million compared with Ps.5,348.1 million in second-quarter 2019, mainly explained by the growth in broadband RGUs.

Second-quarter operating segment income increased by 0.7%, reaching Ps.2,321.4 million compared with Ps.2,305.6 million in second-quarter 2019. The margin was 42.1%.


Second-quarter sales decreased by 16.3% to Ps. 6,740.6 million compared with Ps.8,050.0 million in second-quarter 2019.

Millions of Mexican pesos





Change %







Network Subscription






Licensing and Syndication






Net Sales





Second-quarter Advertising sales decreased by 33.1% to Ps.2,922.2 million compared with Ps.4,370.3 million in second-quarter 2019. The decrease in sales is explained by a significant deterioration in the Mexican economy due to COVID-19 that resulted in a reduction of advertising budgets in many categories, such as Food and Beverage, Retail, Telecom, Travel, and Out-of-Home Entertainment.

Network Subscription

Second-quarter Network Subscription sales increased by 16.1% to Ps.1,400.7 million compared with Ps.1,206.0 million in second-quarter 2019. This growth is mainly related to the increase in the price we charge our affiliate distributors for our pay TV networks and to the favorable impact of the depreciation of the Mexican peso on our dollar-denominated revenues.

Licensing and Syndication 

Second-quarter Licensing and Syndication sales decreased by 2.3% to Ps.2,417.7 million from Ps.2,473.7 million in second-quarter 2019. We estimate that royalties from Univision reached U.S.$79.7 million in second-quarter 2020 compared to U.S.$99.6 million in second-quarter 2019. This decrease in royalties is mainly explained by the impact that COVID-19 had in advertising budgets in the US. The depreciation of the Mexican peso partially compensated the decrease in royalties.

Second-quarter operating segment income decreased by 28.9% to Ps.2,080.8 million compared with Ps.2,928.3 million in second-quarter 2019. This decrease is mainly explained by the drop in advertising sales. The margin was 30.9%.

Other Businesses

Second-quarter sales decreased by 67.1% to Ps.567.1 million compared with Ps.1,725.7 million in second-quarter 2019. The decrease is mainly explained by a decline in revenues in our soccer, gaming, publishing and film distribution businesses due to the measures triggered by the outbreak of COVID-19, which included the suspension of activities in some businesses of this segment, including gaming and sports.

Second-quarter operating segment loss was Ps.422.4 million compared with an income of Ps.148.8 million in second-quarter 2019.

Corporate Expense

Corporate expense decreased by Ps.73.2 million, or 16.7%, to Ps.366.0 million in second-quarter 2020, from Ps.439.2 million in second-quarter 2019. The decrease reflected primarily a lower share-based compensation expense.

Share-based compensation expense in second-quarter 2020 and 2019 amounted to Ps.193.9 million and Ps.251.8 million, respectively, and was accounted for as corporate expense. Share-based compensation expense is measured at fair value at the time the equity benefits are conditionally sold to officers and employees, and is recognized over the vesting period.

Other Expense, Net

Other expense, net, increased by Ps.10.5 million, or 3.7%, to Ps.293.5 million in second-quarter 2020, from Ps.283.0 million in second-quarter 2019. The favorable change in cash Other expense, net, reflected primarily a one-time cash reimbursement in connection to Imagina Media Audiovisual, S.L., a former associate of the Company, partially offset by higher non-recurring severance expenses, and higher expenses related to legal and financial advisory professional services.

The increase in non-cash Other expense, net, reflected primarily a higher loss on disposition of property and equipment.

The following table sets forth the breakdown of cash and non-cash other income (expense), net, stated in millions of Mexican pesos, for the three months ended June 30, 2020 and 2019.

Other income (expense), net












Finance Expense, Net

The following table sets forth finance (expense) income, net, stated in millions of Mexican pesos for the quarters ended June 30, 2020 and 2019.





Interest expense




Interest income




Foreign exchange gain, net




Other finance expense, net




Finance expense, net




Finance expense, net, decreased by Ps.2,179.6 million, to Ps.88.9 million in second-quarter 2020 from Ps.2,268.5 million in second-quarter 2019.

This favorable change reflected primarily:

(i)  a Ps.2,026.2 million increase in foreign exchange gain, net, resulting primarily from the favorable effect of a 3.5% appreciation of the Mexican peso against the U.S. dollar in second-quarter 2020 compared with a 1.2% appreciation in second-quarter 2019, on a higher average net U.S. dollar liability position;

(ii)  a Ps.359.4 million decrease in other finance expense, net, resulting from a lower loss in fair value of our derivative contracts in second-quarter 2020; and

(iii)  a Ps.102.8 million increase in interest income explained primarily by a higher average amount of cash and cash equivalents in second-quarter 2020. 

These favorable variances were partially offset by a Ps.308.8 million increase in interest expense, primarily due to a higher average principal amount of debt in second-quarter 2020.

Share of Income of Associates and Joint Ventures, Net

Share of income of associates and joint ventures, net, decreased by Ps.26.2 million, or 16.0%, to Ps.137.6 million in second-quarter 2020 from Ps.163.8 million in second-quarter 2019. This decrease reflected mainly a lower share of the estimated income of Univision Holdings, Inc. (“UHI”), the controlling company of Univision Communications Inc., which was partially offset by a higher share of income of Ocesa Entretenimiento, S.A. de C.V. (“OCEN”), a live entertainment company in Mexico, Central America and Colombia, primarily in connection with a share of income related to the period in which we classified OCEN as a current asset held for sale.

Share of income of associates and joint ventures, net, for the second-quarter 2020, includes primarily our share of income of UHI and OCEN.

Income Taxes

Income taxes increased by Ps.10.6 million, or 1.4%, to Ps.752.5 million in second-quarter 2020 compared with Ps.741.9 million in second-quarter 2019. This increase reflected a higher income tax base, primarily in connection with the appreciation of the Mexican peso against the U.S. dollar in second-quarter 2020, which effect was offset by a lower effective income tax rate.

Net Income Attributable to Non-controlling Interests

Net income attributable to non-controlling interests decreased by Ps.94.4 million, or 27.4%, to Ps.249.9 million in second-quarter 2020, compared with Ps.344.3 million in second-quarter 2019. This decrease reflected primarily a lower portion of net income attributable to non-controlling interests in our Sky segment.

Capital Expenditures

During second-quarter 2020, we invested approximately U.S.$196.4 million in property, plant and equipment as capital expenditures. The following table sets forth the breakdown by segment of capital expenditures for second-quarter 2020 and 2019.

Capital Expenditures

Millions of U.S.$









Content and Other Businesses






For the full year 2020, we maintain our guidance in capital expenditures is in the range of U.S.$750 million to U.S.$800 million.

Debt, Lease Liabilities and Other Notes Payable

The following table sets forth our total consolidated debt, lease liabilities and other notes payable as of June 30, 2020 and December 31, 2019. Amounts are stated in millions of Mexican pesos.

June 30, 2020

December 31, 2019




Current portion of long-term debt




Long-term debt, net of current portion




Total debt 1




Current portion of lease liabilities




Long-term lease liabilities, net of current portion




Total lease liabilities




Current portion of other notes payable



Total other notes payable



Total debt, lease liabilities and other notes payable




 As of June 30, 2020 and December 31, 2019, total debt is presented net of finance costs in the amount of Ps.1,427.6 million and Ps.1,441.6 million, respectively.

As of June 30, 2020, our consolidated net debt position (total debt and lease liabilities, less cash and cash equivalents, temporary investments, and non-current investments in financial instruments) was Ps.109,037.5 million. As of June 30, 2020, the non-current investments in financial instruments amounted to an aggregate of Ps.9,381.7 million.

On June 19, 2020 Standard & Poor´s Global Ratings ratified the BBB+ ratings for the Company and on June 24, 2020 Fitch Ratings also ratified the BBB+ ratings for the Company.


On July 2, 2020, we concluded the sale of our 50% equity stake in Sistema Radiópolis, S.A. de C.V. (“Radiópolis”) in the amount of Ps.1,248 million, of which Ps.713.4 million were paid in cash by the acquirer in the first half of 2020, and received the payment of a dividend from Radiópolis in the amount of Ps.285.6 million. As of June 30, 2020, the consolidated net assets of Radiópolis were presented as current assets and liabilities held for sale in our consolidated statement of financial position.

Shares Outstanding

As of June 30, 2020 and December 31, 2019, our shares outstanding amounted to 329,940.8 million and 337,244.3 million shares, respectively, and our CPO equivalents outstanding amounted to 2,820.0 million and 2,882.4 million CPO equivalents, respectively. Not all of our shares are in the form of CPOs. The number of CPO equivalents is calculated by dividing the number of shares outstanding by 117.

As of June 30, 2020 and December 31, 2019, the GDS (Global Depositary Shares) equivalents outstanding amounted to 564.0 million and 576.5 million GDS equivalents, respectively. The number of GDS equivalents is calculated by dividing the number of CPO equivalents by five.


During second quarter 2020, the Organization of American States extended its recognition to Televisa for implementing a social responsibility campaign due to the contingency derived from the COVID-19 outbreak.

In addition, the Company was selected as a constituent of the S&P/BMV Total Mexico ESG Index, recently launched by S&P Dow Jones and the Mexican Stock Exchange.

Furthermore, Televisa was nominated by the 2020 Latin American Sustainable Leaders Agenda (ALAS20) initiative as “Leading Company in Sustainability” and “Leading Company in Corporate Governance”.

COVID-19 Impact

The COVID-19 pandemic has affected our business, financial position and results of operations for the quarter ended June 30, 2020, and it is currently difficult to predict the degree of the impact on the third quarter and the remainder of 2020. 

We cannot guarantee that conditions in the bank lending, capital and other financial markets will not continue to deteriorate as a result of the pandemic, or that our access to capital and other sources of funding will not become constrained, which could adversely affect the availability and terms of future borrowings, renewals or refinancings. In addition, the deterioration of global economic conditions as a result of the pandemic may ultimately reduce the demand of our products across our segments as our clients and customers reduce or defer their spending.

While the pandemic has evolved and some parts of Mexico have started to resume activities partially, a significant part of the population is still implementing social distancing and shelter-in-place policies. As a result, during the quarter ended June 30, 2020, this has affected, and is still affecting the ability of our employees, suppliers and customers to conduct their functions and businesses in their typical manner. The Mexican Government has established a plan to reactivate economic activities in accordance with color-based phases determined on a weekly basis in every state of the country. To this date, most of the country’s states are on phase red or orange, meaning most of non-essential economic activities remain closed or, in the case of orange, open with strict limitations. Furthermore, federal and local governments have also established guidelines for businesses re-openings, which may be burdensome or expensive to implement.  Media and telecommunications are not included in the suspension as they are considered essential economic activities. We have continued operating our essential businesses uninterrupted to continue benefiting the country with connectivity, entertainment and information, while also promoting the “stay at home” policy whenever possible, in order to take safety and cautionary measures for our employees. To date, our “Stay at home with Televisa” campaign, which promotes serenity, entertainment and social cohesion among audiences and brands, has reached 46 million people.

As described above, our Content business faced a significant reduction in the demand for advertising during the quarter ended June 30, 2020 and may continue to be affected by the reduction in the level of economic activity in the jurisdictions in which our customers are located. We are partially dependent on the demand for advertising from consumer-focused companies, and the COVID-19 pandemic has caused, and could further cause, advertisers to reduce, postpone or, in a few cases, eliminate their advertisement spending on our platforms. We have recently re-started our production of new content following the requirements and health guidelines imposed by the Mexican Government.

In our Other Businesses segment, sporting and other entertainment events for which we have broadcast rights, or which we organize, promote and/or are located in venues we own, were suspended for most of the quarter ended June 30, 2020, but some of them have recently started to operate again. Moreover, during the quarter ended June 30, 2020, most of our non-essential businesses, including casinos, were closed. When local authorities start to approve the re-opening of these venues in the cities where we operate, rules will be enacted which may include capacity and operating hours restrictions; these may affect the results of our Other Businesses segment in the following months.  As of this date, just one of our casinos has re-started operations.

The magnitude of the impact on our business will depend on the duration and extent of the COVID-19 pandemic and the impact of federal, state, local and foreign governmental actions, including continued or future social distancing, and consumer behavior in response to the COVID-19 pandemic and such governmental actions. Due to the evolving and uncertain nature of this situation, we are not able to estimate the full extent of the impact of the COVID-19 pandemic, but it may continue affecting our business, financial position and results of operations over the near, medium or long-term.

Additional Information Available on Website

The information in this press release should be read in conjunction with the financial statements and footnotes contained in the Company’s Annual Report and on Form 20-F for the year ended December 31, 2019, which are available on the “Reports and Filings” section of our investor relations website at

About Televisa

Televisa is a leading media company in the Spanish-speaking world, an important cable operator in Mexico and an operator of a leading direct-to-home satellite pay television system in Mexico. Televisa distributes the content it produces through several broadcast channels in Mexico and in over 70 countries through 25 pay-tv brands, television networks, cable operators and over-the-top or “OTT” services. In the United States, Televisa’s audiovisual content is distributed through Univision Communications Inc. (“Univision”) the leading media company serving the Hispanic market. Univision broadcasts Televisa’s audiovisual content through multiple platforms in exchange for a royalty payment. In addition, Televisa has equity and warrants which upon their exercise would represent approximately 36% on a fully-diluted, as-converted basis of the equity capital in Univision Holdings, Inc., the controlling company of Univision. Televisa’s cable business offers integrated services, including video, high-speed data and voice services to residential and commercial customers as well as managed services to domestic and international carriers. Televisa owns a majority interest in Sky, a leading direct-to-home satellite pay television system and broadband provider in Mexico, operating also in the Dominican Republic and Central America. Televisa also has interests in magazine publishing and distribution, professional sports and live entertainment, feature- film production and distribution, and gaming.


This press release contains forward-looking statements regarding the Company’s results and prospects. Actual results could differ materially from these statements. The forward-looking statements in this press release should be read in conjunction with the factors described in “Item 3. Key Information – Forward Looking Statements” in the Company’s Annual Report on Form 20 – F, which, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this press release and in oral statements made by authorized officers of the Company. Statements contained in this release relating to the COVID-19 outbreak, the impact of which on our business performance and financial results remains inherently uncertain, are forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

(Please see attached tables for financial information and ratings data)

Contact Information

Investor Relations 
Tel: (52 55) 5261 2445

Carlos Madrazo. VP, Head of Investor Relations / 
Santiago Casado. Investor Relations Director. /

Media Relations:

Rubén Acosta / Tel: (52 55) 5224 6420 /
Teresa Villa / Tel: (52 55) 4438 1205 /



AS OF JUNE 30, 2020 AND DECEMBER 31, 2019

(Millions of Mexican Pesos)

June 30,

December 31,





(Audited) 1

Current assets:

Cash and cash equivalents





Trade notes and accounts receivable, net



Other accounts and notes receivable, net



Derivative financial instruments



Due from related parties



Transmission rights and programming






Contract costs



Assets held for sale



Other current assets



Total current assets



Non-current assets:

Derivative financial instruments



Transmission rights and programming



Investments in financial instruments



Investments in associates and joint ventures



Property, plant and equipment, net



Right-of-use assets



Intangible assets, net



Deferred income tax assets



Contract costs



Other assets



Total non-current assets



Total assets





Our 40% equity interest in OCEN in the amount of Ps.694.0 million as of December 31, 2019, was previously reported as part of current assets held for sale, and has been classified to investments in associates and joint ventures as of that date to conform with the presentation of this investment as of June 30, 2020.




AS OF JUNE 30, 2020 AND DECEMBER 31, 2019

(Millions of Mexican Pesos)

June 30,

December 31,






Current liabilities:

Current portion of long-term debt





Interest payable



Current portion of lease liabilities



Current portion of other notes payable


Derivative financial instruments


Trade accounts payable and accrued expenses



Customer deposits and advances



Other advances related to the Radiopolis’ sale


Income taxes payable



Other taxes payable



Employee benefits



Due to related parties



Liabilities related to assets held for sale



Other current liabilities



Total current liabilities



Non-current liabilities:

Long-term debt, net of current portion



Lease liabilities, net of current portion



Derivative financial instruments



Income taxes payable



Deferred income tax liabilities



Post-employment benefits



Other long-term liabilities



Total non-current liabilities



Total liabilities




Capital stock



Additional paid-in-capital





Retained earnings:

Legal reserve



Unappropriated earnings



Net (loss) income for the period





Accumulated other comprehensive (loss) income, net



Shares repurchased





      Equity attributable to stockholders of the Company



Non-controlling interests



Total equity



Total liabilities and equity









(Millions of Mexican Pesos)

Three months ended June 30,

Six months ended June 30,









Net sales









Cost of sales





Selling expenses





Administrative expenses





Income before other expense





Other expense, net





Operating income





Finance expense





Finance income





Finance expense, net





Share of income (loss) of associates and joint

ventures, net





Income (loss) before income taxes





Income taxes (expense) benefits





Net income (loss)









Net income (loss) attributable to:

Stockholders of the Company









Non-controlling interests





Net income (loss)









Basic earnings (loss) per CPO attributable to

stockholders of the Company











Cision View original content:

SOURCE Grupo Televisa, S.A.B.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of CCL, CSPR and ASG of Upcoming Deadlines

WILMINGTON, Del., July 07, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies:

Carnival Corporation (NYSE:



Class Period: January 28, 2020 – May 1, 2020
Lead Plaintiff Deadline: July 27, 2020

According to the Complaint, on May 1, 2020, The Wall Street Journal published an article titled “Cruise Ships Set Sail Knowing the Deadly Risk to Passengers and Crew,” which detailed how cruise ships, including Carnival ships, facilitated the spread of COVID-19 and provided new facts about early warning signs Carnival and its cruise lines possessed and the Company’s related COVID-19 disclosure failures.  The article also noted that testimony from an investigation in Australia revealed that Carnival and its cruise lines may have misled shore officials by concealing those exhibiting COVID-19 symptoms before docking.  On the same day, it was revealed that the Chair of the House Committee on Transportation and Infrastructure and Chair of the House Subcommittee on Coast Guard and Maritime Transportation had initiated a records request regarding the response of Carnival to Covid-19 or other infectious disease outbreaks aboard cruise ships.

To learn more, visit:

Casper Sleep, Inc. (NYSE:



Attention: All persons or entities that purchased the common stock of Casper Sleep in or traceable to the Company’s public offering conducted on or around February 7, 2020 (“IPO”)
Lead Plaintiff Deadline: August 18, 2020

According to the Complaint, on January 10, 2020, the Company filed its Registration Statement on Form S-l for the IPO, which, after several amendments, was declared effective by the SEC on February 5, 2020 (the “Registration Statement”).  On February 7, 2020, Casper filed its Prospectus on Form 424B4 with the SEC.  In the IPO, defendants sold 8.35 million shares of Casper common stock at $12 per share, generating over $100 million in gross proceeds.

Then, on April 21, 2020, Casper announced that it was taking significant actions to improve its cash position and business model, notwithstanding the fact that the Company had raised more than $100 million in gross offering proceeds from the IPO less than three months previously.  The Company stated that it was reducing the size of its global operations and sales team and completely winding down its European operations, leading to the loss of 21% of its entire corporate workforce globally. These drastic measures were necessitated by the Company’s ballooning losses and deteriorating cash position. The Company also stated that defendant Macfarlane, the Company’s CFO and COO, was resigning – an extraordinary move so soon after the IPO.

On May 12, 2020, Casper issued a release providing its financial results for the quarter ended March 31, 2020 – the same quarter during which defendants conducted the IPO.  The Company stated that it had suffered a net loss of $34.5 million, a 98% increase year over year, and an adjusted EBITDA loss of $22.9 million, a 60% increase year over year.  In addition, the Company stated that its gross margin had actually fallen during the quarter by 190 basis points.

To learn more, visit:

PlayAGS, Inc. (NYSE:



Class Period: August 2, 2018 – August 7, 2019
Lead Plaintiff Deadline: August 24, 2020

According to the Complaint, on August 7, 2019, PlayAGS reported a net loss of $7.6 million for second quarter 2019, which included a $3.5 million impairment to goodwill and $1.3 million impairment to intangible assets of the Company’s iGaming reporting unit, due to extended regulatory timelines which delayed revenues.

To learn more, visit:

If you would like to discuss any of these lawsuits and your rights cost and obligation free, please contact Seth D. Rigrodsky or Timothy J. MacFall toll-free at (888) 969-4242 or  by e-mail at

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.


Rigrodsky & Long, P.A.                                      
Seth D. Rigrodsky
Timothy J. MacFall
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530

FILING DEADLINE–Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ENPH, LOPE and PRA

CEDARHURST, N.Y., July 07, 2020 (GLOBE NEWSWIRE) — The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.

Grand Canyon Education, Inc. (LOPE)

Investors Affected: January 5, 2018 and January 27, 2020
Lead Plaintiff Motion Deadline: July 13, 2020
Shareholders may find more information at

Enphase Energy, Inc. (ENPH)

Investors Affected: February 26, 2019 and June 17, 2020
Lead Plaintiff Motion Deadline: August 17, 2020
Shareholders may find more information at 

ProAssurance Corporation (PRA)

Investors Affected: April 26, 2019 and May 7, 2020
Lead Plaintiff Motion Deadline: August 17, 2020
Shareholders may find more information at 

Shareholders who purchased shares in these companies during the dates listed are encouraged to contact us via the case links above, by calling toll-free at 1-833-835-1495 or by email (

If you wish to serve as lead plaintiff with the goal of overseeing the litigation to obtain a fair and just resolution, you must petition the Court on or before the deadlines provided above.

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967